Eli Lilly announced that its investigational drug, sofetabart mipitecan, received FDA Breakthrough Therapy designation for the treatment of platinum-resistant ovarian cancer.
- The stock is currently trading at $1037.81 (down 0.06%), demonstrating significant resilience compared to the broader market sell-off (S&P 500 down 1.52%) amid trade tensions.
- The designation was officially granted on January 20, 2026.